Literature DB >> 2565844

Costs of medical and surgical treatment of duodenal ulcer.

A Sonnenberg1.   

Abstract

Proximal gastric vagotomy and intermittent and maintenance therapy with H2-antagonists have all been claimed to be effective in long-term management of duodenal ulcer disease. The model of a Markov chain was used to compare their costs by a medical decision analysis. The high price of the initial procedure made proximal gastric vagotomy the most expensive therapy, its costs rising from +10,600 after 1 yr to +12,200 after 15 yr. The average costs of intermittent therapy per patient rose from +500 to +7500. Maintenance therapy cost as much as intermittent therapy but provided 8% and 4% more time spent free of ulcer relapse and pain, respectively. In a sensitivity analysis, the order of the therapeutic options regarding their cost-effectiveness remained robust to changes in the assumptions underlying the model. In a European health care system, the initial surgical procedure cost only one-seventh of the average annual income compared with two-thirds in the United States, and proximal gastric vagotomy turned out to be the cheapest therapy after 6 yr. These results suggest that maintenance therapy provides the best long-term management. Gastric surgery may represent a cost-effective measure of ulcer prevention in Europe but not in the United States.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2565844     DOI: 10.1016/0016-5085(89)90511-8

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  14 in total

1.  Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions.

Authors:  R J Lipsy
Journal:  Pharmacoeconomics       Date:  1992-04       Impact factor: 4.981

2.  Cost savings with antacid treatment?

Authors:  D W Piper
Journal:  Pharmacoeconomics       Date:  1993-02       Impact factor: 4.981

3.  A requiem for vagotomy.

Authors:  D Johnston; I G Martin
Journal:  BMJ       Date:  1991-04-20

Review 4.  Omeprazole: a pharmacoeconomic evaluation of its use in duodenal ulcer and reflux oesophagitis.

Authors:  L B Barradell; D McTavish
Journal:  Pharmacoeconomics       Date:  1993-06       Impact factor: 4.981

Review 5.  Ranitidine: a pharmacoeconomic evaluation of its use in acid-related disorders.

Authors:  J E Frampton; D McTavish
Journal:  Pharmacoeconomics       Date:  1994-07       Impact factor: 4.981

Review 6.  Formulary management of antiulcer drugs: economic considerations.

Authors:  P P Tucker; D B Nash
Journal:  Pharmacoeconomics       Date:  1994-04       Impact factor: 4.981

7.  Varying efficacy of Helicobacter pylori eradication regimens: cost effectiveness study using a decision analysis model.

Authors:  A E Duggan; K Tolley; C J Hawkey; R F Logan
Journal:  BMJ       Date:  1998-05-30

8.  Current medical management of peptic ulcer disease.

Authors:  B E Lukie
Journal:  Can Fam Physician       Date:  1989-10       Impact factor: 3.275

Review 9.  Prescribing policy for antiulcer treatment in the elderly.

Authors:  G Bianchi Porro; M Lazzaroni
Journal:  Drugs Aging       Date:  1993 Jul-Aug       Impact factor: 3.923

10.  "Proton-pump inhibitor-first" strategy versus "step-up" strategy for the acute treatment of reflux esophagitis: a cost-effectiveness analysis in Japan.

Authors:  Yasuki Habu; Kazuo Maeda; Takeo Kusuda; Takuya Yoshino; Seiji Shio; Maki Yamazaki; Takanobu Hayakumo; Kyohei Hayashi; Yoshiyuki Watanabe; Keiichi Kawai
Journal:  J Gastroenterol       Date:  2005-11       Impact factor: 6.772

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.